ANAVEX LIFE SCIENCES CORP. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ANAVEX LIFE SCIENCES CORP. (AVXL) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $23.18 million as of 2025-09-30, per its 10-K/A filed 2026-08-28.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-08-28
- 2025-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $23.18M.
- 2024-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $21.09M.
- 2023-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $18.59M.
- 2022-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $13.37M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-09-30 | $23.18M 10-K/A · filed 2026-08-28 | |
| 2024-09-30 | $21.09M 10-K/A · filed 2026-08-28 | |
| 2023-09-30 | $18.59M 10-K · filed 2024-12-23 | |
| 2022-09-30 | $13.37M 10-K · filed 2023-11-27 | |
| 2021-09-30 | $10.45M 10-K · filed 2023-11-27 | |
| 2020-09-30 | $8.28M 10-K · filed 2021-11-24 | |
| 2019-09-30 | $6.57M 10-K · filed 2020-12-28 | |
| 2018-09-30 | $4.68M 10-K · filed 2019-12-16 | $3.15M 10-K · filed 2018-12-12 |
| 2017-09-30 | $3.39M 10-K · filed 2019-01-25 | |
| 2016-09-30 | $2.00M 10-K · filed 2019-01-25 | |
| 2015-09-30 | $581.00K 10-K · filed 2017-12-11 | |
| 2014-09-30 | $441.00K 10-K · filed 2015-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |